Coronary endothelial function testing provides superior discrimination compared with standard clinical risk scoring in prediction of cardiovascular events by Reriani, Martin et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Coronary endothelial function testing provides superior discrimination
compared with standard clinical risk scoring in prediction of cardiovascular
events
Reriani, Martin; Sara, Jaskanwal D; Flammer, Andreas J; Gulati, Rajiv; Li, Jing; Rihal, Charanjit;
Lennon, Ryan; Lerman, Lilach O; Lerman, Amir
Abstract: BACKGROUND Endothelial dysfunction is regarded as the early stage of atherosclerosis and is
associated with cardiovascular (CV) events. This study was designed to determine whether assessment of
coronary endothelial function (CEF) is safe and can reclassify risk in patients with early coronary artery
disease beyond the Framingham risk score (FRS). METHODS AND RESULTS CEF was evaluated using
intracoronary acetylcholine in 470 patients who presented with chest pain and nonobstructive coronary
artery disease. CV events were assessed after a median follow-up of 9.7 years. The association between
CEF and CV events was examined, and the net reclassification improvement index (NRI) was used to
compare the incremental contribution of CEF when added to FRS.The mean age was 53 years, and 68%
of the patients were women with a median FRS of 8. Complications (coronary dissection) occurred in
three (0.6%) and CV events in 61 (13%) patients. In univariate analysis, microvascular CEF [hazard
ratio (HR) 0.85, 95% confidence interval (CI) 0.72-0.97, P=0.032] and epicardial CEF (HR 0.73, 95%
CI 0.59-0.90, P=0.01) were found to be significant predictors of CV events, whereas FRS was not (HR
1.05, 95% CI 0.85-1.26, P=0.61). When added to FRS, microvascular CEF correctly reclassified 11.3%
of patients [NRI 0.11 (95% CI 0.019-0.21)], epicardial CEF correctly reclassified 12.1% of patients [NRI
0.12 (95% CI -0.02 to 0.26)], and the combined microvascular and epicardial CEF correctly reclassified
22.8% of patients [NRI 0.23 (95% CI 0.08-0.37)]. CONCLUSION CEF testing is safe and adds value
to the FRS, with superior discrimination and risk stratification compared with FRS alone in patients
presenting with chest pain or suspected ischemia.
DOI: https://doi.org/10.1097/MCA.0000000000000347
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-134342
Published Version
Originally published at:
Reriani, Martin; Sara, Jaskanwal D; Flammer, Andreas J; Gulati, Rajiv; Li, Jing; Rihal, Charanjit;
Lennon, Ryan; Lerman, Lilach O; Lerman, Amir (2016). Coronary endothelial function testing provides
superior discrimination compared with standard clinical risk scoring in prediction of cardiovascular events.
Coronary artery disease, 27(3):213-220.
DOI: https://doi.org/10.1097/MCA.0000000000000347
Coronary endothelial function testing provides superior
discrimination compared with standard clinical risk scoring in
prediction of cardiovascular events
Martin Reriani, Jaskanwal D. Sara, Andreas J. Flammer, Rajiv Gulati, Jing Li,
Charanjit Rihal, Ryan Lennon, Lilach O. Lerman and Amir Lerman
Background Endothelial dysfunction is regarded as the
early stage of atherosclerosis and is associated with
cardiovascular (CV) events. This study was designed to
determine whether assessment of coronary endothelial
function (CEF) is safe and can reclassify risk in patients with
early coronary artery disease beyond the Framingham risk
score (FRS).
Methods and results CEF was evaluated using
intracoronary acetylcholine in 470 patients who presented
with chest pain and nonobstructive coronary artery disease.
CV events were assessed after a median follow-up of
9.7 years. The association between CEF and CV events was
examined, and the net reclassification improvement index
(NRI) was used to compare the incremental contribution of
CEF when added to FRS. The mean age was 53 years, and
68% of the patients were women with a median FRS of 8.
Complications (coronary dissection) occurred in three
(0.6%) and CV events in 61 (13%) patients. In univariate
analysis, microvascular CEF [hazard ratio (HR) 0.85, 95%
confidence interval (CI) 0.72–0.97, P= 0.032] and epicardial
CEF (HR 0.73, 95% CI 0.59–0.90, P= 0.01) were found to be
significant predictors of CV events, whereas FRS was not
(HR 1.05, 95% CI 0.85–1.26, P= 0.61). When added to FRS,
microvascular CEF correctly reclassified 11.3% of patients
[NRI 0.11 (95% CI 0.019–0.21)], epicardial CEF correctly
reclassified 12.1% of patients [NRI 0.12 (95% CI − 0.02 to
0.26)], and the combined microvascular and epicardial CEF
correctly reclassified 22.8% of patients [NRI 0.23 (95% CI
0.08–0.37)].
Conclusion CEF testing is safe and adds value to the FRS,
with superior discrimination and risk stratification
compared with FRS alone in patients presenting with chest
pain or suspected ischemia. Coron Artery Dis 27:213–220
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Introduction
Globally, cardiovascular (CV) diseases are the number
one cause of death and a leading cause of morbidity [1].
Traditional CV risk factors based on the Framingham
study have been used to estimate an individual global CV
risk [2]. Practice guidelines use the Framingham risk
score (FRS) to classify individuals as low, intermediate, or
high risk and to determine their target cholesterol levels
for primary prevention [3].
However, these traditional risk factors as identified in the
Framingham study have been inconsistent in predicting
CV events when applied to different populations and
correctly assigned the risk of the development of cor-
onary heart disease only in half of the cases [4]. This
underscores the complex interplay between traditional
CV risk factors, genetic predisposition, and other ather-
oprotective factors prevalent in individuals of different
populations in predicting CV events.
Functional vascular abnormalities such as endothelial
dysfunction are considered a key event in the initiation,
progression, and complications of coronary artery disease.
Endothelial dysfunction is a systemic disorder affecting
multiple vascular beds and can be considered as the
integrated index of both the overall CV risk factor burden
and the sum of genetic risk factors and environmental
factors [4].
Previous studies have shown an association between the
presence of both coronary and systemic endothelial
dysfunction and an increased risk for future CV events
[5–8]. We have previously summarized the role of
endothelial function testing in predicting CV events [9].
No published studies, however, have evaluated how
measures of coronary endothelial function (CEF) affect
discrimination of the FRS.
Invasive measurement of the change in coronary blood
flow (CBF) in response to an intracoronary infusion of
acetylcholine (ACh) is considered the reference standard
in CEF testing [10]. However, the invasive nature and
potential safety concerns of this method limit its use [10].
To our knowledge, no previous study has compared the
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efficacy of the FRS with that of invasive CEF in pre-
dicting CV events. This study was designed to test the
hypothesis that coronary epicardial and microvascular
endothelial function testing is safe and improves the
predictive accuracy and classification of the FRS in
patients with nonobstructive coronary artery disease.
Methods
Study design
This study is a prospective single-center cohort study.
The study was approved by the Mayo Clinic Institutional
Review Board, and informed consent was obtained from
all patients.
Study population
The study group consisted of 470 patients with chest
pain who were referred to the cardiac catheterization
laboratory for evaluation of coronary artery disease, were
found to have nonobstructive disease, and underwent a
comprehensive coronary physiology study, including
assessment of endothelial dependent and independent
functions.
Exclusion criteria included the following: significant
coronary artery stenosis (> 40%), ejection fraction less
than 45%, unstable angina, previous acute coronary syn-
drome, significant systemic disease, and pregnancy.
Medications that may affect CV hemodynamics were
discontinued for at least 48 h before the study.
Study protocol
At baseline, diagnostic coronary angiography and deter-
mination of endothelium-dependent changes in CBF and
endothelium-independent coronary flow reserve were
performed as described previously [11–14]. A Doppler
guidewire (0.014 inches in diameter; FloWire; Volcano
Incorporated, San Diego, California, USA) within a 2.2 F
coronary infusion catheter (Ultrafuse; SciMed Life
Systems, Maple Grove, Minnesota, USA) was advanced
and positioned in the middle portion of the left anterior
descending coronary artery (LAD). Intracoronary bolus
injections of incremental doses (18–72 µg) of adenosine
(Fujisawa, Kanagawa, Japan), an endothelium-
independent vasodilator (primarily of the microcircula-
tion) [15], were administered into the guiding catheter
until maximal hyperemia was achieved.
Assessment of endothelium-dependent changes in vas-
cular diameter and CBF was performed by selective
infusion of ACh into the LAD. ACh (10–6, 10–5, and
10–4mol/l; Iolab Pharmaceuticals, Rancho Cucamonga,
California, USA) was infused at a rate of 1 ml/min for
3 min [12,16]. Hemodynamic data (heart rate and mean
arterial pressure), Doppler measurements, and coronary
angiography data were obtained after each infusion.
Endothelium-independent epicardial vasodilation was
assessed with an intracoronary bolus injection of
nitroglycerin (200 µg; Abbott Laboratories, Abbott Park,
Illinois, USA) [17].
Epicardial coronary endothelial function
The coronary artery diameter was analyzed by quantita-
tive coronary angiograms from digital images using a
modification of a previously described technique from
this institution [11,12]. The LAD was divided into
proximal, middle, and distal segments. For each segment,
measurements were performed in the region in which the
greatest change had occurred during ACh infusion. An
angiographically smooth segment of the proximal, mid-
dle, and distal LAD, free from any overlapping branch
vessels, was identified in each patient and served as the
reference diameter for the calculation of the diameter of
stenosis. End-diastolic cine frames that best showed the
segment were selected, and calibration of the video and
cine images was done, identifying the diameter of the
guide catheter. Quantitative measurements of the cor-
onary arteries were obtained using a computer-based
image analysis system. Segment diameters were deter-
mined at baseline and after both ACh and nitroglycerin
administration. The proximal segment was not exposed
to ACh and thus served as a control segment.
Microvascular coronary endothelial function
Doppler flow velocity spectra were analyzed online to
determine the time-averaged peak velocity. Volumetric
CBF was determined from the following relation:
CBF= cross-sectional area× average peak velocity× 0.5
[18]. Endothelium-dependent microvascular function
was calculated as % ΔCBF in response to ACh as pre-
viously described [19].
Follow-up
Long-term follow-up was performed through a detailed
questionnaire inquiring about occurrence and dates and
timings of CV events. The vital status of the patients was
determined using the National Death Index. For patients
experiencing more than one CV event, only the first
event was considered in the analysis. All CV events were
confirmed by a review of the hospital records.
A composite endpoint of CV death, acute myocardial
infarction, stroke, coronary artery bypass graft surgery,
repeat coronary angiography, and percutaneous coronary
intervention and other vascular surgeries (endarter-
ectomy, repair of an abdominal aortic aneurysm, or
peripheral bypass surgeries) was assessed during the
follow-up.
Statistical analysis
Data are expressed as mean ± SD or count and percen-
tage, as appropriate. Variables with heavily skewed dis-
tribution are reported as medians with first and third
quartiles in parentheses. The statistical analysis was
carried out by an independent statistician.
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Survival analysis
The starting point for all survival analysis was the date of
the CEF angiogram. The composite of CV events was
the primary endpoint, and the patient’s survival time was
the interval from the date of the endothelial function
angiogram to the date of the first event. For patients who
did not have an event, the event-free survival time was
the interval from the endothelial function angiogram to
December 2010.
The FRS was then calculated for each patient using the
original variables of the 10-year FRS (age, sex, cigarette
smoking status, blood pressure, antihypertensive medi-
cation use, total cholesterol level, high-density lipopro-
tein level, and the presence of diabetes mellitus) [2]. The
FRS score was then refitted using a multivariable Cox
proportional-hazards model. This baseline model was
then extended to three other models by including
microvascular CEF (% ΔCBF), then epicardial CEF
(% ΔCAD), and finally both microvascular and epicardial
CEF. For each of the models, the 10-year absolute risk of
developing CV events was calculated and used to classify
patients as low (< 10%), intermediate (10–20%), and high
(>20%) risk on the basis of the Adult Treatment Panel
III classification [3].
The Cox proportional-hazards multivariable regress-
ion analysis was used to determine the univariate and
multivariable relationships between the FRS, micro-
vascular CEF, epicardial CEF, and CV events during the
follow-up period. All probability values were two-tailed,
and a P-value of 0.05 was considered statistically
significant.
Net reclassification improvement index
The net reclassification improvement index (NRI) was
calculated to assess whether microvascular CEF, epi-
cardial CEF, or combined microvascular and epicardial
CEF improved discrimination of the FRS using methods
developed by Pencina et al. [20]. The NRI calculates the
percentage of correct movement across categories for
those with and those without events. The NRI assesses
the probability of being correctly reclassified to a higher
risk category for patients with events minus the prob-
ability of being incorrectly reclassified to a lower risk
category for patients with events plus the probability of
being correctly reclassified to a lower risk category for
patients with no events minus the probability of being
incorrectly classified to a higher risk category for patients
with no events. As the risk prediction models were based
on time-to-event data, the NRI was calculated using
methods that took survival time into account [21,22].
The corresponding 95% confidence intervals (CIs) were
obtained with bootstrapping.
Results
Study cohort
We studied 470 patients with a mean ± SD age of
53 ± 12 years, 68% of whom were women. The median
(IQR) FRS was 8 (4.2–15.2).
The % ΔCBF (mean ± SD) was 61.5 ± 164.6 and the
% ΔCAD was − 15.2 ± 24.8. The baseline characteristics
of the cohort at the time of coronary vascular testing are
shown in Tables 1 and 2.
Patients were enrolled in this study between 1 December
1992 and 31 May 2009. After a follow-up period of
9.7 years (6.1, 14.0) [median (Q1, Q3)], 61 patients (13%)
experienced a CV event, including cardiac death, myo-
cardial infarction, repeat angiogram/angioplasty, stroke,
coronary artery bypass graft surgery, and other vascular
surgeries (carotid endarterectomy and peripheral vascular
bypass; Tables 3 and 4).
Complications
Invasive coronary vasomotion testing was complicated by
a procedure-related coronary dissection in three (0.6%) of
470 patients, all of which occurred before 2007. One of
the dissections was mild and did not require stenting.
The other two were managed with stenting, and the
patients did well after the procedure. There were no
deaths or myocardial infarctions associated with the pro-
cedure during the study period.
Framingham risk score
In univariate analysis, the FRS did not significantly
predict the CV events [hazard ratio (HR) per 10% of
predicted risk: 1.05, 95% CI 0.85–1.26, P= 0.61]. The
estimated 10-year risk based on the FRS placed all 470
Table 1 Baseline patient characteristics by tertiles of Framingham
risk score
Variables Low Intermediate High P
N (%) 277 (59) 117 (25) 76 (16)
Age (mean ±SD) (years) 48 ± 11 57 ±9 62 ±8 <0.001
Female [N (%)] 228 (82) 66 (56) 26 (34) <0.001
BMI (kg/m2) 28 ± 6 29 ±6 29 ±6 0.27
Hypertension [N (%)] 80 (29) 58 (50) 49 (64) <0.001
Diabetes [N (%)] 10 (4) 11 (9) 19 (25) <0.001
Hypercholesterolemia [N (%)] 139 (50) 84 (72) 57 (75) <0.001
Family history CAD [N (%)] 167 (61) 82 (71) 48 (65) <0.2
Aspirin [N (%)] 121 (44) 62 (53) 40 (52) 0.15
ACE inhibitor [N (%)] 33 (12) 31 (27) 10 (13) <0.001
β-Blockers [N (%)] 81 (29) 34 (29) 21 (28) 0.96
Ca2+ channel blocker [N (%)] 80 (29) 48 (41) 28 (37) 0.04
Lipid lowering [N (%)] 102 (37) 55 (47) 29 (38) 0.16
Oral hypoglycemic [N (%)] 6 (2) 4 (3) 11 (14) <0.001
Insulin use [N (%)] 5 (2) 5 (4) 3 (4) 0.31
% ΔCBF 69 ±193 47 ±118 57 ± 98 0.48
% ΔCAD −14.8 ± 25 −16.3 ±25 −15.2 ±21 0.85
CFR 2.95 ± 0.7 2.7 ±0.7 2.9 ±0.6 <0.001
Values are expressed as mean ±SD or N (%).
% ΔCAD, percent change in coronary artery diameter to acetylcholine; % ΔCBF,
percent change in coronary blood flow to acetylcholine; CFR, coronary flow
reserve.
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patients in the intermediate risk category (10–20% risk)
[3]. There was no difference in the incidence of CV
events when patients were classified in the low (< 10%),
intermediate (10–20%), and high (>20%) risk categories
on the basis of the FRS Adult Treatment Panel III
classification (P= 0.08 by Kaplan–Meier analysis; Fig. 1).
Microvascular coronary endothelial function
In univariate analysis microvascular CEF (% ΔCBF) was
a significant predictor of CV events (HR per 50%
increase in ΔCBF: 0.85, 95% CI 0.72–0.97, P= 0.032).
The incidence of CV events was not different between
patients with normal microvascular function and those
with microvascular endothelial dysfunction (micro-
vascular endothelial dysfunction was defined as ≤ 50%
increase in CBF in response to the maximal dose of ACh
compared with baseline CBF; P= 0.36 by Kaplan–Meier
analysis; Fig. 2). After adjusting for the FRS, micro-
vascular CEF was no longer a significant predictor of CV
events (HR per 50% increase in ΔCBF: 0.88, 95% CI
0.74–1.01). When added to the FRS, microvascular CEF
correctly reclassified 11.3% of the patients (NRI 0.11,
95% CI 0.019–0.21, P= 0.02). Eleven percent of the
patients with events were incorrectly classified in a lower
category and 21% of the patients with no events were
correctly classified in a lower risk category, providing a
net correct reclassification of 11.3% (Table 3).
Epicardial coronary endothelial function
In univariate analysis, epicardial CEF (% ΔCAD) sig-
nificantly predicted CV events (HR per 20% increase in
ΔCAD: 0.73, 95% CI 0.59–0.90, P= 0.01). The incidence
of CV events was significantly greater in patients with
epicardial endothelial dysfunction than in those
Table 2 Baseline patient characteristics by microvascular
endothelial function
Variables
Microvascular
endothelial
dysfunction
Normal
microvascular
endothelial function P
N (%) 265 (56) 117 (25)
Age (mean ±SD) (years) 54 ±12 52 ±12 0.03
Female [N (%)] 186 (70) 134 (65) 0.27
BMI (kg/m2) 29 ±6 28 ± 6 0.48
Hypertension [N (%)] 114 (43) 73 (46) 0.09
Diabetes [N (%)] 25 (9) 15 (7) 0.41
Hypercholesterolemia [N (%)] 157 (59) 123 (60) <0.85
Family history CAD [N (%)] 178 (69) 119 (60) <0.04
Aspirin [N (%)] 138 (52) 85 (41) 0.02
ACE inhibitor [N (%)] 42 (15) 32 (16) 0.94
β-Blockers [N (%)] 80 (30) 56 (27) 0.50
Ca2+ -channel blocker [N (%)] 94 (35) 62 (30) 0.25
Lipid lowering [N (%)] 118 (45) 68 (33) 0.01
Oral hypoglycemic [N (%)] 13 (5) 8 (4) 0.6
Insulin use [N (%)] 8 (3) 5 (2) 0.70
% ΔCBF −10.9 ± 36 155 ±212 <0.001
% ΔCAD −25.4 ±21 −2.1 ±23 <0.001
CFR 2.78 ±0.66 2.98 ±0.7 <0.001
Values are expressed as mean ±SD or N (%).
% ΔCAD, percent change in coronary artery diameter to acetylcholine; % ΔCBF,
percent change in coronary blood flow to acetylcholine; CFR, coronary flow
reserve.
Table 3 Distribution of cardiovascular events in the patient
population by tertiles of Framingham risk score
Variable Low Intermediate High P
N=61 277 (59) 117 (25) 76 (16)
Cardiac death [n (%)] 1 (0.3) 2 (1.7) 2 (2.6) 0.01
Myocardial infarction [n (%)] 1 (0.3) 2 (1.7) 0 0.04
Repeat angiogram/PCI [n (%)] 18 (6.4) 14 (11.9) 6 (7.8) 0.11
Stroke [n (%)] 3 (1) 0 0 0.24
CABG [n (%)] 3 (1) 4 (3.4) 2 (2.6) 0.26
Other vascular surgery [n (%)] 1 (0.3) 2 (1.7) 0 0.16
Values are expressed as n (%).
CABG, coronary artery bypass surgery; other vascular surgery includes endar-
terectomy and peripheral vascular bypass surgery.
Table 4 Distribution of cardiovascular events in the patient population by microvascular endothelial function
Variables Microvascular endothelial dysfunction Normal microvascular endothelial function P
N (%) 265 (56) 117 (25)
Cardiac death [n (%)] 3 (1.2) 2 (1.7) 0.01
Myocardial infarction [n (%)] 2 (0.8) 1 (0.8) 0.04
Repeat angiogram/PCI [n (%)] 25 (9.4) 13 (11.1) 0.11
Stroke [n (%)] 3 (1.2) 0 0.24
CABG [n (%)] 4 (1.5) 5 (4.3) 0.26
Other vascular surgery [n (%)] 1 (0.3) 2 (1.7) 0.16
CABG, coronary artery bypass surgery; other vascular surgery includes endarterectomy and peripheral vascular bypass surgery.
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Framingham risk score is divided into low (<10%), intermediate
(10–20%), and high (>20%) risk on the basis of the ATPIII
classification. ATPIII, Adult Treatment Panel III.
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vasodilated with ACh (P= 0.02 by Kaplan–Meier analy-
sis; Fig. 3). After adjusting for the FRS, epicardial CEF
remained a significant predictor of CV events (HR per
20% increase in ΔCAD: 0.76, 95% CI 0.61–0.96). When
added to the FRS, epicardial CEF correctly reclassified
12.1% of the patients (NRI 0.12, 95% CI − 0.02 to 0.26,
P= 0.09), but it did not reach statistical significance. Five
percent of patients with events were incorrectly classified
in a lower category, and 23% of patients with no events
were correctly classified in a lower risk category, yielding
an NRI of 12.1% (Table 3).
When added to the FRS, the combined microvascular
and epicardial CEF correctly reclassified 22.8% of the
patients (NRI 0.23, 95% CI 8–36.7%, P= 0.001). Only
3% of the patients with events were incorrectly classified
in a lower category and 26% of patients with no events
were correctly classified in a lower risk category, yielding
a net correct reclassification of 22.8% (Tables 3 and 5).
Subanalysis in diabetics
To assess whether the FRS and CEF could predict the
risk for CV events differently in patients with diabetes
mellitus, we assessed separately for an interaction
between diabetes and FRS, microvascular CEF, and
epicardial CEF. No test for interaction yielded a sig-
nificant result (P-value for FRS, 0.68; P-value for micro-
vascular CEF, 0.56; and P-value for epicardial CEF,
0.79), suggesting that the risk for CV events predicted by
the FRS, microvascular CEF, and epicardial CEF did not
vary significantly between patients with and those with-
out diabetes.
Discussion
The present study demonstrates that CEF testing is safe
and adds significant value to the FRS, providing greater
discrimination power for risk stratification of patients
without obstructive coronary artery disease. The combi-
nation of microvascular and epicardial CEF provided the
greatest value to FRS, with more than one in five indi-
viduals being correctly reclassified. Microvascular and
epicardial endothelial function when used alone also
provided modest value to the FRS with 12 and 11% of
individuals, respectively, being reclassified correctly.
The model incorporating epicardial CEF alone did not
reach statistical significance. Thus, the current study
further supports the clinical utility of individual assess-
ment of endothelial dysfunction in risk stratification.
Traditional CV risk factors are not sufficient to correctly
assign risk of development of CV disease in up to 50% of
cases [23]. Indeed, the FRS, when applied to different
populations, has shown inconsistent predictive value
[24,25]. For example, the mortality data for the first
20 years in 12 cohorts of six countries showed that tra-
ditional risk factors are associated with risk only within
certain cohorts [26]. Only age and mean blood pressure
were universal predictors of coronary heart disease. In the
current study, all patients were classified as intermediate
risk when their 10-year absolute risk was calculated using
the FRS alone. In univariate and multivariable models,
the FRS was indeed not a significant predictor of CV
events. Thus, there is a need for a more comprehensive
method to assess risk in these individuals without CAD.
Several studies have tested different novel risk markers
for improving CV risk assessment, especially in indivi-
dual with intermediate risk [27,28], by providing greater
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discrimination of higher-risk and lower-risk patients
within the intermediate-risk group [28]. AHA practice
guidelines for assessment of CV risk in asymptomatic
adults give recommendations on appropriate test mod-
alities to further define risk in patients with intermediate
risk [29]. In this study, we show that CEF testing in
patients presenting with chest pain and found to have
nonobstructive coronary artery disease on the diagnostic
angiogram correctly reclassifies 22% of the patients with
intermediate risk on the basis of the FRS, with potential
implications on risk management of these individuals.
Administration of intracoronary ACh is considered the
reference standard in the assessment of epicardial and
microvascular endothelial function [10]. Its use in clinical
practice, however, still remains limited, possibly because
of safety concerns related to its invasive nature. In the
recent guidelines of the European Society of Cardiology
on the management of stable coronary artery disease, the
use of intracoronary ACh for assessment of CEF was
endorsed and labeled as a class IIa indication [30],
underscoring the need for better risk stratification in
these patients. In the present study we demonstrate that
comprehensive intracoronary physiology assessment to
determine endothelial function is safe when performed
by experienced operators. Our findings are consistent
with those of a previous report demonstrating the safety
of the assessment of endothelial function in women [31].
Additional barriers to adoption of this test are the lack of
standardization of the testing protocol and difficulty in
interpreting the results. Moreover, although several
strategies aimed at reducing CV risk factors are associated
with improvement in endothelial health, no single agent
to date has been approved for the treatment of endo-
thelial dysfunction per se [32]. Nevertheless, recent stu-
dies have shown that treatment of CV risk factors, which
leads to improvement of peripheral endothelial function
(vs. persistent endothelial dysfunction), is associated with
an improved CV prognosis [33,34].
Several studies have shown an association between
endothelial dysfunction (both in coronary and systemic
circulation) as a marker of atherosclerotic risk and CV
prognosis in patients with and those without coronary
artery disease [5,7,8,35,36]. Endothelial dysfunction can
be considered as a functional expression of inherent
atherosclerotic risk, representing an integrated index of
both the overall CV risk factor burden and the sum of all
vasculoprotective factors in an individual. It may provide
the link between CV risk factors and the progression of
atherosclerotic disease [37].
Previous studies have shown that most atherosclerotic
plaques responsible for future acute coronary syndromes
occur in lesions associated with minimal luminal stenosis
[38,39]. Lesion-related characteristics are thus crucial in
determining vulnerable plaques in mild stenotic lesions
and, by extension, in identifying patients at risk for car-
diac events (vulnerable patients). We have previously
shown that segments of the coronary epicardial arteries
with endothelial dysfunction are associated with plaque
characteristics typical of vulnerable plaques [40] and with
the presence of a lipid core [14]. Moreover, segments
with endothelial dysfunction are also those that ulti-
mately progress to atherosclerotic plaques [14]. Thus,
endothelial dysfunction may be an integral element in
the evolution of a vulnerable plaque. Vulnerable plaques
may be a potential mechanism by which coronary endo-
thelial dysfunction causes an increase in CV events in
vulnerable patients, and, thus, its detection may aid in
more accurate risk stratification of patients classified as
being at intermediate risk.
Study limitations
There are several limitations to our study. First, CV
events were determined through questionnaires filled by
the patients. A reviewer verified the events that occurred
at our institution. We were, however, limited in verifying
events that occurred elsewhere. Furthermore, the
response rate for our questionnaires was 43%, which is
comparable to that in other studies but is still a limitation
of this study.
Second, we did not have intravascular ultrasound data on
all patients to ascribe the site of endothelial dysfunction
to the culprit coronary arteries. This would have provided
a stronger link between segmental epicardial endothelial
dysfunction and site of coronary CV events.
Third, our study was not designed to measure whether
improvement in endothelial function with treatment
Table 5 Net reclassification improvement for CV events with addition of CEF to FRS (N= 470)
Variable % Reclassified Low (<10%) Intermediate (10–20%) High (>20%) % Net correct reclassification NRI
FRS+microvascular CEF
Events 11.5 7 54 0 0 0.11
Nonevents 21.5 87 321 1 21.2
FRS+epicardial CEF
Events 27.9 10 44 7 −4.9 0.12
Nonevents 30.3 110 285 14 23.5
FRS+microvascular and epicardial CEF
Events 26.2 9 45 7 −3.3 0.228
Nonevents 31.5 119 280 10 26.6
CEF, coronary endothelial function; CV, cardiovascular; FRS, Framingham risk score; NRI, net reclassification improvement index.
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improves the prognosis of future CV events. Patients
diagnosed with endothelial dysfunction may have been
provided with treatment (at their physician’s discretion),
which might have improved endothelial function and led
to regression to the mean of our results.
Fourth, there may have been a selection bias in the
study, as the patients included in the study had a clinical
indication for cardiac catheterization and may have
potentially been different from the general population for
whom the FRS was intended.
Conclusion
We demonstrated that, among patients presenting with
chest pain or suspected ischemia, the assessment of CEF
is safe, adds value to the FRS, and correctly reclassifies
patients in the intermediate-risk category. This poten-
tially has implications in risk management and treatment
of these individual patients, and could be used in further
risk stratification of patients, especially belonging to the
intermediate-risk category with implications on risk
reduction strategies.
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